Keymed Biosciences Inc. (2162.HK)
HKD 33.0
(-1.93%)
HKD 33.0
(-1.93%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 3.88 Billion CNY | -1.26% |
| 2022 | 3.93 Billion CNY | -0.05% |
| 2021 | 3.93 Billion CNY | 642.43% |
| 2020 | 529.94 Million CNY | -19.53% |
| 2019 | 658.57 Million CNY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 3.8 Billion CNY | 0.0% |
| 2024 Q1 | 3.8 Billion CNY | -2.0% |
| 2023 Q3 | 3.88 Billion CNY | -4.54% |
| 2023 FY | 3.88 Billion CNY | -1.26% |
| 2023 Q2 | 4.06 Billion CNY | 0.0% |
| 2023 Q4 | 3.88 Billion CNY | 0.0% |
| 2023 Q1 | 4.06 Billion CNY | 3.44% |
| 2022 Q2 | 4.1 Billion CNY | 0.0% |
| 2022 Q1 | 4.1 Billion CNY | 4.29% |
| 2022 FY | 3.93 Billion CNY | -0.05% |
| 2022 Q4 | 3.93 Billion CNY | 0.0% |
| 2022 Q3 | 3.93 Billion CNY | -4.17% |
| 2021 FY | 3.93 Billion CNY | 642.43% |
| 2021 Q4 | 3.93 Billion CNY | 0.0% |
| 2021 Q3 | 3.93 Billion CNY | 212.39% |
| 2021 Q2 | 1.25 Billion CNY | 0.0% |
| 2021 Q1 | 1.25 Billion CNY | 137.66% |
| 2020 FY | 529.94 Million CNY | -19.53% |
| 2020 Q4 | 529.94 Million CNY | 0.0% |
| 2020 Q3 | 529.94 Million CNY | 0.0% |
| 2020 Q1 | - CNY | 0.0% |
| 2019 FY | 658.57 Million CNY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 409.99 Million HKD | -847.073% |
| CK Life Sciences Int'l., (Holdings) Inc. | 11.24 Billion HKD | 65.477% |